Click Therapeutics, Inc.

It was a true honor for Click Therapeutics to be nominated for the "Best Startup" award at the 2025 Prix Galien USA Awards last week! It was an extraordinary evening celebrating fellow innovators in the healthcare space. Representing Click was David Benshoof Klein, Founder and CEO, and Sarah Jackson, Head of Business Development and Alliance Management. This nomination celebrates the impact of prescription digital therapeutics and Software-Enhanced Drugs™. We’re focused on creating a new, digital-first standard of care that improves health outcomes. The rapid evolution of healthcare needs innovators, and Click is ready to continue leading the charge. Congratulations to the winners of this year's Prix Galien Awards—you inspire us all! #PrixGalien #HealthcareInnovation #FutureOfMedicine #DigitalTherapeutics

An exciting few days at #CNSSummit2025! Thank you to everyone who joined us in discussing the future of patient care; these collaborations are what will turn innovation into impact.

Click Founder and CEO, David Benshoof Klein, will be speaking at the Digital Implementation Summit, hosted by Pfizer in Cambridge, Massachusetts, on November 5th. David is joining Anthony Costello, CEO of Medidata Solutions, in a joint session to discuss "A New Era for Clinical Trials: Software-Enhanced Drug™ Treatments." In this session, David and Anthony will introduce Software-Enhanced Drug™ Therapies and explain their impact on clinical trials, healthcare access, and patient outcomes. They will cover how, as the pharmaceutical industry evolves toward more holistic, patient-centered care models, Software-Enhanced Drug™ Treatments are emerging as a powerful strategy to differentiate products and improve outcomes. Check out the full event agenda here: https://lnkd.in/eyTDybmb #ClinicalTrials #HealthcareInnovation #SoftwareEnhancedDrugs  #DigitalTherapeutics #Medidata #ClickTherapeutics

Join Click Therapeutics CEO & Founder David Benshoof Klein in conversation with Medidata Solutions CEO Anthony Costello at CNS Summit in Boston, November 2-5. As prescription digital therapeutics move from innovation to integration, forums like CNS Summit are essential for advancing the science, policy, and practice that will define the future of care. CNS Summit embodies what we believe in: innovating and collaborating to transform patient outcomes. #DigitalTherapeutics #CNS #MentalHealth #HealthcareInnovation #SoftwareEnhancedDrugs

Looking forward to #CNSSummit2025! Viveca Livezey, MD, FAAN, who leads our clinical development will be in attendance - we are looking forward to connecting with leaders who are shaping the next chapter of digital therapeutics.

The Click Therapeutics team is LIVE at #HLTH2025! Swing by booth #4632 to meet the brains behind our science, design, and innovation, get the scoop on our latest pipeline breakthroughs, and snag some fresh popcorn while you’re at it. We can't wait to connect and talk about harnessing the power of Software Enhanced Drugs™ to transform outcomes for patients. #DigitalTherapeutics #HLTH #HealthcareInnovation #PharmaPartnerships #ClickTherapeutics #SoftwareEnhancedDrugs

Are we entering an era where an app is just as critical to treatment as a pill? Find out what Software-Enhanced Drugs™ means for patients, pharma, and clinical trials. https://lnkd.in/e6Mwz2Pd #DigitalTherapeutics #FutureofHealthcare #MedTech #PharmaInnovation #ClinicalTrials #SoftwareEnhancedDrugs

Today, Click Therapeutics and Boehringer Ingelheim presented the positive data from the pivotal Phase III CONVOKE study, which met its primary endpoint, at the 38th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam. The trial evaluated the effectiveness and safety of CT-155, an investigational prescription digital therapeutic intended for use as an adjunct treatment for the negative symptoms of schizophrenia. The data presented showed a statistically significant reduction in experiential negative symptoms of schizophrenia, as treatment with CT-155 demonstrated a Cohen’s D effect size of -0.36 (p value= 0.0003) in the Clinical Assessment Interview for Negative Symptoms - Motivation and Pleasure (CAINS-MAP) subscale score at 16 weeks, reflective of a 6.8-point improvement in negative symptoms severity versus a Digital Control improvement of 4.2-points.  CONVOKE is the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia as an adjunct to standard of care antipsychotic therapy. In addition, the data showed that CT-155 was well-tolerated with a favorable safety profile, with numerically fewer adverse events (AEs) than in the digital control (8.3% vs 13.4%, respectively). There were no adverse events (AEs) related to study treatment. Patients in the study also had high engagement with the app in both arms (CT-155 70.4% versus Digital Control 76.5%) over the course of the study. Approximately 2.8 million people in the US live with schizophrenia, and about 60% of them experience negative symptoms,  which can include lack of motivation and social withdrawals. Unfortunately, there are no FDA-approved treatments indicated specifically for the treatment of these negative symptoms of schizophrenia, which is viewed as one of the largest unmet needs for this patient population, as demonstrated by the Breakthrough Designation status granted by FDA to CT-155. Looking ahead, Boehringer Ingelheim and Click Therapeutics are conducting the multicenter Enspirus study (NCT06791122), a prospective cohort study, to evaluate the clinical effectiveness, engagement, healthcare resource utilization, and safety of CT-155 in patients with negative symptoms of schizophrenia in a real-world-like setting. Read the full release: https://lnkd.in/eFQphE7T #Schizophrenia #DigitalTherapeutics #PrescriptionDigitalTherapeutics #ECNP2025

#NEWS: Today we presented pivotal data from our Phase III clinical study of our investigational prescription digital therapeutic that evaluated negative symptoms of schizophrenia at the European College of Neuropsychopharmacology (ECNP) Congress and full results will be published at a later date.   We remain grateful to everyone involved in this study and to our valued partners, Click Therapeutics, Inc., for their collaboration.   Learn more: https://lnkd.in/eDxnPEq6

Today, Click Therapeutics and Boehringer Ingelheim presented the positive data from the pivotal Phase III CONVOKE study, which met its primary endpoint, at the 38th European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam. The trial evaluated the effectiveness and safety of CT-155, an investigational prescription digital therapeutic intended for use as an adjunct treatment for the negative symptoms of schizophrenia. The data presented showed a statistically significant reduction in experiential negative symptoms of schizophrenia, as treatment with CT-155 demonstrated a Cohen’s D effect size of -0.36 (p value= 0.0003) in the Clinical Assessment Interview for Negative Symptoms - Motivation and Pleasure (CAINS-MAP) subscale score at 16 weeks, reflective of a 6.8-point improvement in negative symptoms severity versus a Digital Control improvement of 4.2-points.  CONVOKE is the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia as an adjunct to standard of care antipsychotic therapy. In addition, the data showed that CT-155 was well-tolerated with a favorable safety profile, with numerically fewer adverse events (AEs) than in the digital control (8.3% vs 13.4%, respectively). There were no adverse events (AEs) related to study treatment. Patients in the study also had high engagement with the app in both arms (CT-155 70.4% versus Digital Control 76.5%) over the course of the study. Approximately 2.8 million people in the US live with schizophrenia, and about 60% of them experience negative symptoms,  which can include lack of motivation and social withdrawals. Unfortunately, there are no FDA-approved treatments indicated specifically for the treatment of these negative symptoms of schizophrenia, which is viewed as one of the largest unmet needs for this patient population, as demonstrated by the Breakthrough Designation status granted by FDA to CT-155. Looking ahead, Boehringer Ingelheim and Click Therapeutics are conducting the multicenter Enspirus study (NCT06791122), a prospective cohort study, to evaluate the clinical effectiveness, engagement, healthcare resource utilization, and safety of CT-155 in patients with negative symptoms of schizophrenia in a real-world-like setting. Read the full release: https://lnkd.in/eFQphE7T #Schizophrenia #DigitalTherapeutics #PrescriptionDigitalTherapeutics #ECNP2025